<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title>Critical Care</journal-title><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19439067</article-id><article-id pub-id-type="pmc">2717426</article-id><article-id pub-id-type="publisher-id">cc7874</article-id><article-id pub-id-type="doi">10.1186/cc7874</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Deane</surname><given-names>Adam M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>adam.deane@adelaide.edu.au</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Chapman</surname><given-names>Marianne J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>Marianne.Chapman@health.sa.gov.au</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Fraser</surname><given-names>Robert JL</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>robert.fraser@adelaide.edu.au</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Burgstad</surname><given-names>Carly M</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>Carly.Burgstad@health.sa.gov.au</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Besanko</surname><given-names>Laura K</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Laura.Besanko@health.sa.gov.au</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Horowitz</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>michael.horowitz@adelaide.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>University of Adelaide, Discipline of Anaesthesia and Intensive Care, North Terrace, Adelaide, 5000, South Australia, Australia</aff><aff id="I2"><label>2</label>Royal Adelaide Hospital, Department of Intensive Care, North Terrace, Adelaide, 5000 South Australia, Australia</aff><aff id="I3"><label>3</label>Investigation and Procedures Unit, Repatriation General Hospital, Daws Road, Daw Park, 5041, South Australia, Australia</aff><aff id="I4"><label>4</label>University of Adelaide, Discipline of Medicine, North Terrace, Adelaide, 5000 South Australia, Australia</aff><aff id="I5"><label>5</label>Royal Adelaide Hospital, Department of Gastroenterology, North Terrace, Adelaide, 5000 South Australia, Australia</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>5</month><year>2009</year></pub-date><volume>13</volume><issue>3</issue><fpage>R67</fpage><lpage>R67</lpage><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/13/3/R67"></ext-link><history><date date-type="received"><day>10</day><month>2</month><year>2009</year></date><date date-type="rev-request"><day>11</day><month>3</month><year>2009</year></date><date date-type="rev-recd"><day>24</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>Copyright © 2009 Deane et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Deane et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="4449" xml_f="4461" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="4472" xml_f="5162" txt_i="24" txt_f="714">Hyperglycaemia occurs frequently in the critically ill, affects outcome adversely, and is exacerbated by enteral feeding. Furthermore, treatment with insulin in this group is frequently complicated by hypoglycaemia. In healthy patients and those with type 2 diabetes, exogenous glucagon-like peptide-1 (GLP-1) decreases blood glucose by suppressing glucagon, stimulating insulin and slowing gastric emptying. Because the former effects are glucose-dependent, the use of GLP-1 is not associated with hypoglycaemia. The objective of this study was to establish if exogenous GLP-1 attenuates the glycaemic response to enteral nutrition in patients with critical illness induced hyperglycaemia.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="5203" xml_f="5210" txt_i="716" txt_f="723">Methods</offsets></title><p><offsets xml_i="5221" xml_f="5730" txt_i="724" txt_f="1233">Seven mechanically ventilated critically ill patients, not previously known to have diabetes, received two intravenous infusions of GLP-1 (1.2 pmol/kg/min) and placebo (4% albumin) over 270 minutes. Infusions were administered on consecutive days in a randomised, double-blind fashion. On both days a mixed nutrient liquid was infused, via a post-pyloric feeding catheter, at a rate of 1.5 kcal/min between 30 and 270 minutes. Blood glucose and plasma GLP-1, insulin and glucagon concentrations were measured.</offsets></p></sec><sec><title><offsets xml_i="5752" xml_f="5759" txt_i="1235" txt_f="1242">Results</offsets></title><p><offsets xml_i="5770" xml_f="5891" txt_i="1243" txt_f="1364">In all patients, exogenous GLP-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC</offsets><sub><offsets xml_i="5896" xml_f="5907" txt_i="1364" txt_f="1375">30–270 min </offsets></sub><offsets xml_i="5913" xml_f="5979" txt_i="1375" txt_f="1441">GLP-1 (2077 ± 144 mmol/l min) vs placebo (2568 ± 208 mmol/l min); </offsets><italic><offsets xml_i="5987" xml_f="5989" txt_i="1441" txt_f="1443">P </offsets></italic><offsets xml_i="5998" xml_f="6092" txt_i="1443" txt_f="1537">= 0.02) and the peak blood glucose (GLP-1 (10.1 ± 0.7 mmol/l) vs placebo (12.7 ± 1.0 mmol/l); </offsets><italic><offsets xml_i="6100" xml_f="6102" txt_i="1537" txt_f="1539">P </offsets></italic><offsets xml_i="6111" xml_f="6242" txt_i="1539" txt_f="1667">&lt; 0.01). The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); </offsets><italic><offsets xml_i="6250" xml_f="6252" txt_i="1667" txt_f="1669">P </offsets></italic><offsets xml_i="6261" xml_f="6509" txt_i="1669" txt_f="1917">= 0.02) but there was no difference in absolute insulin concentrations. There was a transient, non-sustained, reduction in plasma glucagon concentrations during GLP-1 infusion (t = 30 minutes GLP-1 (90 ± 12 pmol/ml) vs. placebo (104 ± 10 pmol/ml); </offsets><italic><offsets xml_i="6517" xml_f="6519" txt_i="1917" txt_f="1919">P </offsets></italic><offsets xml_i="6528" xml_f="6539" txt_i="1919" txt_f="1927">&lt; 0.01).</offsets></p></sec><sec><title><offsets xml_i="6561" xml_f="6572" txt_i="1929" txt_f="1940">Conclusions</offsets></title><p><offsets xml_i="6583" xml_f="6827" txt_i="1941" txt_f="2185">Acute, exogenous GLP-1 infusion markedly attenuates the glycaemic response to enteral nutrition in the critically ill. These observations suggest that GLP-1 and/or its analogues have the potential to manage hyperglycaemia in the critically ill.</offsets></p></sec><sec><title><offsets xml_i="6849" xml_f="6867" txt_i="2187" txt_f="2205">Trial Registration</offsets></title><p><offsets xml_i="6878" xml_f="6954" txt_i="2206" txt_f="2282">Australian New Zealand Clinical Trials Registry number: ACTRN12609000093280.</offsets></p></sec></abstract></article-meta><notes><p>See related commentary by Kovalaske and Gandhi, <ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/13/4/161"></ext-link></p></notes></front><body><sec><title><offsets xml_i="7176" xml_f="7188" txt_i="2291" txt_f="2303">Introduction</offsets></title><p><offsets xml_i="7199" xml_f="7281" txt_i="2304" txt_f="2386">Hyperglycaemia occurs frequently, even in patients without pre-existing diabetes [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7312" xml_f="7313" txt_i="2386" txt_f="2387">1</offsets></xref><offsets xml_i="7320" xml_f="7354" txt_i="2387" txt_f="2421">], and adversely affects outcome [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7385" xml_f="7386" txt_i="2421" txt_f="2422">2</offsets></xref><offsets xml_i="7393" xml_f="7600" txt_i="2422" txt_f="2629">]. For this reason, treatment with insulin is widely used; however, insulin therapy is associated with a substantial risk of hypoglycaemia, which is associated with both short- and long-term adverse events [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7631" xml_f="7632" txt_i="2629" txt_f="2630">3</offsets></xref><offsets xml_i="7639" xml_f="7640" txt_i="2630" txt_f="2631">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7671" xml_f="7672" txt_i="2631" txt_f="2632">4</offsets></xref><offsets xml_i="7679" xml_f="7802" txt_i="2632" txt_f="2755">]. Although the use of parenteral nutrition affords a stable caloric load, which minimises the incidence of hypoglycaemia [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7833" xml_f="7834" txt_i="2755" txt_f="2756">2</offsets></xref><offsets xml_i="7841" xml_f="7933" txt_i="2756" txt_f="2848">], enteral feeding is the preferred method of nutrient delivery in critically ill patients [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7964" xml_f="7965" txt_i="2848" txt_f="2849">5</offsets></xref><offsets xml_i="7972" xml_f="8098" txt_i="2849" txt_f="2975">]. Hence, there is a need for a therapy to manage hyperglycaemia in enterally fed patients without the risk of hypoglycaemia [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8129" xml_f="8130" txt_i="2975" txt_f="2976">6</offsets></xref><offsets xml_i="8137" xml_f="8139" txt_i="2976" txt_f="2978">].</offsets></p><p><offsets xml_i="8146" xml_f="8343" txt_i="2979" txt_f="3176">Exogenous administration of the incretin hormone, glucagon-like peptide-1 (GLP-1), has been shown to normalise blood glucose concentrations both in healthy patients and those with type 2 diabetes [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8374" xml_f="8375" txt_i="3176" txt_f="3177">7</offsets></xref><offsets xml_i="8382" xml_f="8511" txt_i="3177" txt_f="3306">]. This occurs as a result of stimulation of insulin secretion, suppression of glucagon release and slowing of gastric emptying [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8542" xml_f="8543" txt_i="3306" txt_f="3307">7</offsets></xref><offsets xml_i="8550" xml_f="8551" txt_i="3307" txt_f="3308">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8582" xml_f="8583" txt_i="3308" txt_f="3309">8</offsets></xref><offsets xml_i="8590" xml_f="8713" txt_i="3309" txt_f="3432">]. Because the former effects are glucose dependent, the use of GLP-1 does not appear to be associated with hypoglycaemia [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8744" xml_f="8745" txt_i="3432" txt_f="3433">9</offsets></xref><offsets xml_i="8752" xml_f="9068" txt_i="3433" txt_f="3749">]. The effect of GLP-1 on glycaemia in enterally fed critically ill patients has hitherto not been evaluated. The primary aim of this study was to determine whether exogenous GLP-1 attenuates the glycaemic response to small intestinal nutrient infusion in critically ill patients not previously known to be diabetic.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="9119" xml_f="9140" txt_i="3751" txt_f="3772">Materials and methods</offsets></title><sec><title><offsets xml_i="9160" xml_f="9168" txt_i="3773" txt_f="3781">Subjects</offsets></title><p><offsets xml_i="9179" xml_f="9546" txt_i="3782" txt_f="4149">Seven critically ill adult patients (four males, three females, age range 28 to 76 years), predicted to remain mechanically ventilated for more than 48 hours, were studied. Exclusion criteria included pregnancy, pre-existing diabetes, contraindication to enteral feeding or post-pyloric catheter insertion, and previous surgery on the oesophagus, stomach or duodenum.</offsets></p><p><offsets xml_i="9553" xml_f="9856" txt_i="4150" txt_f="4453">The study was approved by the Human Ethics Committee of the Royal Adelaide Hospital and performed according to the Australian National Health and Medical Research Committee guidelines for the conduct of research involving unconscious persons. Written, informed consent was obtained from the next of kin.</offsets></p></sec><sec><title><offsets xml_i="9878" xml_f="9892" txt_i="4455" txt_f="4469">Study protocol</offsets></title><p><offsets xml_i="9903" xml_f="10987" txt_i="4470" txt_f="5554">Patients were studied on two consecutive days, in which they received intravenous GLP-1 or placebo in a randomised, double-blind fashion. Twelve hours prior to the study, a naso-duodenal feeding catheter was inserted and confirmed via abdominal x-ray. On each study day enteral feeding was ceased at least four hours prior to the commencement of the study. Exogenous insulin (Actrapid, Novo-Nordisk, Copenhagen, Denmark) infusion was ceased at least two hours before the commencement of the study drug. Patient weight was provided by a relative and/or estimated by a dietician. Randomisation and reconstitution of synthetic GLP-1-(7–36) amide (Merck Biosciences, Melbourne, Australia), as a solution in 4% albumin, was performed by the Royal Adelaide Hospital Pharmacy department. The study investigators were blinded to each infusion, which were concealed in a glass bottle covered by black plastic. Both GLP-1 (1.2 pmol/kg/min) and placebo (4% albumin) were infused at a rate of 1 ml/min via a central venous catheter for 270 minutes (i.e. t = 0 to 270 min). At t = 30 minute Ensure</offsets><sup><offsets xml_i="10992" xml_f="10994" txt_i="5554" txt_f="5556">® </offsets></sup><offsets xml_i="11000" xml_f="11385" txt_i="5556" txt_f="5941">(Abbott, Melbourne, Australia), a mixed nutrient liquid (64% carbohydrate, 1 kcal/ml), was delivered continuously into the small intestine at a rate of 1.5 ml/min for four hours (i.e. t = 30 to 270 min). An arterial blood sample was obtained every 15 minutes for measurement of blood glucose and at timed intervals for measurements of plasma insulin, GLP-1 and glucagon concentrations.</offsets></p></sec><sec><title><offsets xml_i="11407" xml_f="11420" txt_i="5943" txt_f="5956">Data analysis</offsets></title><p><offsets xml_i="11431" xml_f="12083" txt_i="5957" txt_f="6609">Blood glucose was measured at the bedside using a portable glucometer (Medisense Optimum, Abbott, Melbourne, Australia). Blood was collected, separated by centrifugation and the resulting plasma was stored at -70° until assayed for hormone concentrations. Plasma insulin was measured by ELISA (Diagnostics Systems Laboratories, Webster, Texas, USA) with an inter-assay coefficient of variation (CV) of 6.2%. Total plasma GLP-1 (GLPIT-36HK Linco Research, St. Charles, Missouri, USA) and glucagon (Siemens Medical Solution Diagnostics, Berkeley, California, USA) concentrations were measured by radioimmunoassay, with a CV of 9.2% and 12%, respectively.</offsets></p></sec><sec><title><offsets xml_i="12105" xml_f="12125" txt_i="6611" txt_f="6631">Statistical analysis</offsets></title><p><offsets xml_i="12136" xml_f="12407" txt_i="6632" txt_f="6903">Data are presented as mean ± standard error of the mean. Area under the curve (AUC) was calculated using the trapezoidal rule. The number of patients required to establish a glucose lowering effect of GLP-1 was based on power calculations derived from our previous work [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="12438" xml_f="12439" txt_i="6903" txt_f="6904">8</offsets></xref><offsets xml_i="12446" xml_f="12521" txt_i="6904" txt_f="6979">]. The ratios of insulin/glucose were calculated, as described previously [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="12553" xml_f="12555" txt_i="6979" txt_f="6981">10</offsets></xref><offsets xml_i="12562" xml_f="13019" txt_i="6981" txt_f="7438">]. Statistical analyses were performed using SPSS (Version 15.0, Chicago, Illinois, USA). Distribution and sensitivity analysis, using nonparametric analyses, allowed parametric testing of data. The difference between intervention and placebo was assessed using paired samples; Student's paired t-test and repeated measures analysis of variance. Data were evaluated for potential carry over effect. The null hypothesis was rejected at the 0.05 significance.</offsets></p></sec></sec><sec><title><offsets xml_i="13047" xml_f="13054" txt_i="7441" txt_f="7448">Results</offsets></title><p><offsets xml_i="13065" xml_f="13146" txt_i="7449" txt_f="7530">The study was well tolerated in all patients. Patient details are shown in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="13178" xml_f="13179" txt_i="7530" txt_f="7531">1</offsets></xref><offsets xml_i="13186" xml_f="13187" txt_i="7531" txt_f="7532">.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="13235" xml_f="13242" txt_i="7533" txt_f="7540">Table 1</offsets></label><caption><p><offsets xml_i="13262" xml_f="13306" txt_i="7540" txt_f="7584">Summary demographic data of patients studied</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center"><offsets xml_i="13387" xml_f="13390" txt_i="7585" txt_f="7588">Age</offsets></td><td align="center"><offsets xml_i="13414" xml_f="13427" txt_i="7589" txt_f="7602">Mean 58 years</offsets></td></tr><tr><td align="center"><offsets xml_i="13460" xml_f="13463" txt_i="7603" txt_f="7606">Sex</offsets></td><td align="center"><offsets xml_i="13487" xml_f="13502" txt_i="7607" txt_f="7622">4 male:3 female</offsets></td></tr><tr><td align="center"><offsets xml_i="13535" xml_f="13544" txt_i="7623" txt_f="7632">Diagnosis</offsets></td><td align="center"><offsets xml_i="13568" xml_f="13588" txt_i="7633" txt_f="7653">4 medical:3 surgical</offsets></td></tr><tr><td align="center"><offsets xml_i="13621" xml_f="13642" txt_i="7654" txt_f="7675">APACHE II (admission)</offsets></td><td align="center"><offsets xml_i="13666" xml_f="13673" txt_i="7676" txt_f="7683">Mean 18</offsets></td></tr><tr><td align="center"><offsets xml_i="13706" xml_f="13723" txt_i="7684" txt_f="7701">APACHE II (study)</offsets></td><td align="center"><offsets xml_i="13747" xml_f="13754" txt_i="7702" txt_f="7709">Mean 17</offsets></td></tr><tr><td align="center"><offsets xml_i="13787" xml_f="13814" txt_i="7710" txt_f="7737">Days in intensive care unit</offsets></td><td align="center"><offsets xml_i="13838" xml_f="13849" txt_i="7738" txt_f="7749">Mean 7 days</offsets></td></tr><tr><td align="center"><offsets xml_i="13882" xml_f="13907" txt_i="7750" txt_f="7775">Serum creatinine (μmol/l)</offsets></td><td align="center"><offsets xml_i="13931" xml_f="13943" txt_i="7776" txt_f="7788">Mean 73 μmol</offsets></td></tr><tr><td align="center"><offsets xml_i="13976" xml_f="13995" txt_i="7789" txt_f="7808">Plasma albumin(g/l)</offsets></td><td align="center"><offsets xml_i="14019" xml_f="14030" txt_i="7809" txt_f="7820">Mean 23 g/l</offsets></td></tr><tr><td align="center"><offsets xml_i="14063" xml_f="14076" txt_i="7821" txt_f="7834">Feed tolerant</offsets><sup><offsets xml_i="14081" xml_f="14082" txt_i="7834" txt_f="7835">1</offsets></sup></td><td align="center"><offsets xml_i="14112" xml_f="14133" txt_i="7836" txt_f="7857">5 of 6 tolerant of EN</offsets></td></tr><tr><td align="center"><offsets xml_i="14166" xml_f="14175" txt_i="7858" txt_f="7867">Inotropes</offsets></td><td align="center"><offsets xml_i="14199" xml_f="14234" txt_i="7868" txt_f="7903">1 patient on catecholamine infusion</offsets></td></tr><tr><td align="center"><offsets xml_i="14267" xml_f="14287" txt_i="7904" txt_f="7924">Parenteral nutrition</offsets></td><td align="center"><offsets xml_i="14311" xml_f="14317" txt_i="7925" txt_f="7931">0 of 7</offsets></td></tr><tr><td align="center"><offsets xml_i="14350" xml_f="14356" txt_i="7932" txt_f="7938">Weight</offsets></td><td align="center"><offsets xml_i="14380" xml_f="14391" txt_i="7939" txt_f="7950">Mean 84 kgs</offsets></td></tr><tr><td align="center"><offsets xml_i="14424" xml_f="14460" txt_i="7951" txt_f="7987">Rate of insulin infusion when ceased</offsets><sup><offsets xml_i="14465" xml_f="14466" txt_i="7987" txt_f="7988">2</offsets></sup></td><td align="center"><offsets xml_i="14496" xml_f="14511" txt_i="7989" txt_f="8004">Mean 2.0 U/hour</offsets></td></tr><tr><td align="center"><offsets xml_i="14544" xml_f="14583" txt_i="8005" txt_f="8044">Total insulin dose in previous 24 hours</offsets></td><td align="center"><offsets xml_i="14607" xml_f="14625" txt_i="8045" txt_f="8063">Mean 57 U/24 hours</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="14671" xml_f="14749" txt_i="8064" txt_f="8142">All data refer to results from the first study day unless otherwise specified.</offsets></p><p><sup><offsets xml_i="14761" xml_f="14763" txt_i="8143" txt_f="8145">1 </offsets></sup><offsets xml_i="14769" xml_f="14991" txt_i="8145" txt_f="8367">Patients are feed-tolerant if (over the preceding 24 hours): delivery of nutrient liquid is at the target rate (as determined by on-site dietician) and gastric residual volumes less were than 250 mL in any six-hour period.</offsets></p><p><sup><offsets xml_i="15003" xml_f="15005" txt_i="8368" txt_f="8370">2 </offsets></sup><offsets xml_i="15011" xml_f="15086" txt_i="8370" txt_f="8445">The infusion rate at t = -120 minutes (i.e. when exogenous insulin ceased).</offsets></p><p><offsets xml_i="15093" xml_f="15149" txt_i="8446" txt_f="8502">APACHE = Acute Physiology and Chronic Health Evaluation.</offsets></p></table-wrap-foot></table-wrap><sec><title><offsets xml_i="15196" xml_f="15209" txt_i="8503" txt_f="8516">Blood glucose</offsets></title><p><offsets xml_i="15220" xml_f="15269" txt_i="8517" txt_f="8566">Blood glucose concentrations are shown in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="15299" xml_f="15300" txt_i="8566" txt_f="8567">1</offsets></xref><offsets xml_i="15307" xml_f="15460" txt_i="8567" txt_f="8720">. There was no difference in baseline blood glucose concentration prior to each infusion (t = 0 min GLP-1 7.5 ± 0.4 mmol/l vs. placebo 7.6 ± 0.6 mmol/l; </offsets><italic><offsets xml_i="15468" xml_f="15470" txt_i="8720" txt_f="8722">P </offsets></italic><offsets xml_i="15479" xml_f="15802" txt_i="8722" txt_f="9045">= not significant (NS)). Prior to the commencement of the small intestinal nutrient infusion (t = 30 min) GLP-1 had no effect on blood glucose. On both days, there was an increase in blood glucose concentration in response to intra-duodenal nutrient infusion (t = 180 min GLP-1 9.3 ± 0.6 mmol/l; placebo 12.2 ± 0.9 mmol/l; </offsets><italic><offsets xml_i="15810" xml_f="15812" txt_i="9045" txt_f="9047">P </offsets></italic><offsets xml_i="15821" xml_f="15962" txt_i="9047" txt_f="9185">&lt; 0.01 for both). GLP-1 markedly attenuated the rise in blood glucose (e.g. t = 60 min GLP-1 7.5 ± -0.5 mmol vs. placebo 9.5 ± -0.8 mmol; </offsets><italic><offsets xml_i="15970" xml_f="15972" txt_i="9185" txt_f="9187">P </offsets></italic><offsets xml_i="15981" xml_f="16068" txt_i="9187" txt_f="9271">&lt; 0.01), peak blood glucose (GLP-1 10.1 ± 0.7 mmol/l vs. placebo 12.7 ± 1.0 mmol/l; </offsets><italic><offsets xml_i="16076" xml_f="16078" txt_i="9271" txt_f="9273">P </offsets></italic><offsets xml_i="16087" xml_f="16147" txt_i="9273" txt_f="9330">&lt; 0.01) and decreased the overall glycaemic response (AUC</offsets><sub><offsets xml_i="16152" xml_f="16163" txt_i="9330" txt_f="9341">30–270 min </offsets></sub><offsets xml_i="16169" xml_f="16232" txt_i="9341" txt_f="9404">GLP-1 2077 ± 144 mmol/l min vs. placebo 2568 ± 208 mmol/l min; </offsets><italic><offsets xml_i="16240" xml_f="16242" txt_i="9404" txt_f="9406">P </offsets></italic><offsets xml_i="16251" xml_f="16259" txt_i="9406" txt_f="9414">= 0.02).</offsets></p><fig position="float" id="F1"><label><offsets xml_i="16300" xml_f="16308" txt_i="9415" txt_f="9423">Figure 1</offsets></label><caption><p><offsets xml_i="16328" xml_f="16490" txt_i="9423" txt_f="9585">Exogenous glucagon-like peptide-1 (GLP-1) attenuated the rise in blood glucose levels and the overall glycaemic response to intra-duodenal nutrient infusion. (AUC</offsets><sub><offsets xml_i="16495" xml_f="16506" txt_i="9585" txt_f="9596">30–270 min </offsets></sub><offsets xml_i="16512" xml_f="16575" txt_i="9596" txt_f="9659">GLP-1 2077 ± 144 mmol/l min vs. placebo 2568 ± 208 mmol/l min; </offsets><italic><offsets xml_i="16583" xml_f="16585" txt_i="9659" txt_f="9661">P </offsets></italic><offsets xml_i="16594" xml_f="16634" txt_i="9661" txt_f="9701">= 0.02). Data are mean ± SEM (n = 7). * </offsets><italic><offsets xml_i="16642" xml_f="16644" txt_i="9701" txt_f="9703">P </offsets></italic><offsets xml_i="16653" xml_f="16663" txt_i="9703" txt_f="9710">&lt; 0.05.</offsets></p></caption><graphic xlink:href="cc7874-1"></graphic></fig></sec><sec><title><offsets xml_i="16742" xml_f="16756" txt_i="9712" txt_f="9726">Plasma insulin</offsets></title><p><offsets xml_i="16767" xml_f="16828" txt_i="9727" txt_f="9788">Plasma insulin and insulin:glucose ratio is shown in Figures </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16858" xml_f="16860" txt_i="9788" txt_f="9790">2a</offsets></xref><offsets xml_i="16867" xml_f="16872" txt_i="9790" txt_f="9795"> and </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16902" xml_f="16904" txt_i="9795" txt_f="9797">2b</offsets></xref><offsets xml_i="16911" xml_f="17109" txt_i="9797" txt_f="9995">. There was no difference in plasma insulin concentration at baseline. Plasma insulin increased in response to intra-duodenal nutrient (e.g. t = 270 min GLP-1 79 ± 21 mU/l and placebo 61 ± 17 mU/l; </offsets><italic><offsets xml_i="17117" xml_f="17119" txt_i="9995" txt_f="9997">P </offsets></italic><offsets xml_i="17128" xml_f="17295" txt_i="9997" txt_f="10161">&lt; 0.03 compared with fasting concentration for both days). At 270 minutes, the insulin/glucose ratio was greater with GLP-1 (GLP-1 9.1 ± 2.7 vs. placebo 5.8 ± 1.8; </offsets><italic><offsets xml_i="17303" xml_f="17305" txt_i="10161" txt_f="10163">P </offsets></italic><offsets xml_i="17314" xml_f="17437" txt_i="10163" txt_f="10286">= 0.02); however, there was no difference in absolute plasma insulin concentrations throughout the entire study period (AUC</offsets><sub><offsets xml_i="17442" xml_f="17452" txt_i="10286" txt_f="10296">0–270 min </offsets></sub><offsets xml_i="17458" xml_f="17523" txt_i="10296" txt_f="10361">GLP-1 16,203 ± 5193 mU/l min vs. placebo 14,434 ± 4561 mU/l min; </offsets><italic><offsets xml_i="17531" xml_f="17533" txt_i="10361" txt_f="10363">P </offsets></italic><offsets xml_i="17542" xml_f="17548" txt_i="10363" txt_f="10369">= NS).</offsets></p><fig position="float" id="F2"><label><offsets xml_i="17589" xml_f="17597" txt_i="10370" txt_f="10378">Figure 2</offsets></label><caption><p><offsets xml_i="17617" xml_f="17710" txt_i="10378" txt_f="10471">Plasma Hormone concentrations. There was no increase in total postprandial insulin secretion </offsets><bold><offsets xml_i="17716" xml_f="17719" txt_i="10471" txt_f="10474">(a)</offsets></bold><offsets xml_i="17726" xml_f="17808" txt_i="10474" txt_f="10556">, however the plasma insulin/blood glucose ratio was increased at t = 270 minutes </offsets><bold><offsets xml_i="17814" xml_f="17817" txt_i="10556" txt_f="10559">(b)</offsets></bold><offsets xml_i="17824" xml_f="17915" txt_i="10559" txt_f="10650">. Exogenous glucagon-like peptide-1 (GLP-1) infusion increased plasma GLP-1 concentrations </offsets><bold><offsets xml_i="17921" xml_f="17925" txt_i="10650" txt_f="10654">(c) </offsets></bold><offsets xml_i="17932" xml_f="17999" txt_i="10654" txt_f="10721">and caused a transient, but non-sustained, suppression of glucagon </offsets><bold><offsets xml_i="18005" xml_f="18008" txt_i="10721" txt_f="10724">(d)</offsets></bold><offsets xml_i="18015" xml_f="18048" txt_i="10724" txt_f="10757">. Data are mean ± SEM (n = 7). * </offsets><italic><offsets xml_i="18056" xml_f="18058" txt_i="10757" txt_f="10759">P </offsets></italic><offsets xml_i="18067" xml_f="18077" txt_i="10759" txt_f="10766">&lt; 0.05.</offsets></p></caption><graphic xlink:href="cc7874-2"></graphic></fig></sec><sec><title><offsets xml_i="18156" xml_f="18168" txt_i="10768" txt_f="10780">Plasma GLP-1</offsets></title><p><offsets xml_i="18179" xml_f="18227" txt_i="10781" txt_f="10829">Plasma GLP-1 concentrations are shown in Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="18257" xml_f="18259" txt_i="10829" txt_f="10831">2c</offsets></xref><offsets xml_i="18266" xml_f="18392" txt_i="10831" txt_f="10957">. Fasting plasma GLP-1 concentrations were similar between groups (t = 0 min GLP-1 36 ± 10 pmol/l vs. placebo 38 ± 11 pmol/l; </offsets><italic><offsets xml_i="18400" xml_f="18402" txt_i="10957" txt_f="10959">P </offsets></italic><offsets xml_i="18411" xml_f="18559" txt_i="10959" txt_f="11107">= NS). Exogenous GLP-1 markedly increased plasma GLP-1 concentration within 30 minutes (t = 30 min GLP-1 124 ± 15 pmol/l vs. placebo 43 ± 9 pmol/l; </offsets><italic><offsets xml_i="18567" xml_f="18569" txt_i="11107" txt_f="11109">P </offsets></italic><offsets xml_i="18578" xml_f="18628" txt_i="11109" txt_f="11156">&lt; 0.01) and throughout the infusion period (AUC</offsets><sub><offsets xml_i="18633" xml_f="18643" txt_i="11156" txt_f="11166">0–270 min </offsets></sub><offsets xml_i="18649" xml_f="18719" txt_i="11166" txt_f="11236">GLP-1 31,659 ± 4203 pmol/l min) vs. placebo 10,399 ± 2508 pmol/l min; </offsets><italic><offsets xml_i="18727" xml_f="18729" txt_i="11236" txt_f="11238">P </offsets></italic><offsets xml_i="18738" xml_f="18918" txt_i="11238" txt_f="11415">&lt; 0.01). During GLP-1 infusion, steady state concentrations were achieved after 30 minutes (t = 30 min plasma GLP-1 124 ± 15 pmol/l vs. t = 90 min plasma GLP-1 131 ± 13 pmol/l; </offsets><italic><offsets xml_i="18926" xml_f="18928" txt_i="11415" txt_f="11417">P </offsets></italic><offsets xml_i="18937" xml_f="18943" txt_i="11417" txt_f="11423">= NS).</offsets></p></sec><sec><title><offsets xml_i="18965" xml_f="18980" txt_i="11425" txt_f="11440">Plasma glucagon</offsets></title><p><offsets xml_i="18991" xml_f="19042" txt_i="11441" txt_f="11492">Plasma glucagon concentrations are shown in Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19072" xml_f="19074" txt_i="11492" txt_f="11494">2d</offsets></xref><offsets xml_i="19081" xml_f="19211" txt_i="11494" txt_f="11624">. Fasting glucagon concentrations were similar between study days (t = 0 min GLP-1 106 ± 14 pmol/ml vs. placebo 102 ± 13 pmol/ml; </offsets><italic><offsets xml_i="19219" xml_f="19221" txt_i="11624" txt_f="11626">P </offsets></italic><offsets xml_i="19230" xml_f="19377" txt_i="11626" txt_f="11773">= NS). There was a decrease in plasma glucagon from baseline during GLP-1 infusion (t = 30 min GLP-1 90 ± 12 pmol/ml vs. placebo 104 ± 10 pmol/ml; </offsets><italic><offsets xml_i="19385" xml_f="19387" txt_i="11773" txt_f="11775">P </offsets></italic><offsets xml_i="19396" xml_f="19436" txt_i="11775" txt_f="11812">&lt; 0.01), which was non-sustained (AUC</offsets><sub><offsets xml_i="19441" xml_f="19455" txt_i="11812" txt_f="11826">0–270 minutes </offsets></sub><offsets xml_i="19461" xml_f="19531" txt_i="11826" txt_f="11896">GLP-1 22,786 ± 6040 pmol/l min vs. placebo 25,830 ± 2644 pmol/l min); </offsets><italic><offsets xml_i="19539" xml_f="19541" txt_i="11896" txt_f="11898">P </offsets></italic><offsets xml_i="19550" xml_f="19556" txt_i="11898" txt_f="11904">= NS).</offsets></p></sec></sec><sec><title><offsets xml_i="19584" xml_f="19594" txt_i="11907" txt_f="11917">Discussion</offsets></title><p><offsets xml_i="19605" xml_f="19912" txt_i="11918" txt_f="12225">This is the first study to evaluate the effect of exogenous GLP-1 infusion on the glycaemic response to enteral nutrition during critical illness. Given the need to avoid hyperglycaemia and hypoglycaemia in critically ill patients, an assessment of the effect of exogenous GLP-1 is of considerable interest.</offsets></p><p><offsets xml_i="19919" xml_f="20143" txt_i="12226" txt_f="12450">The dose of GLP-1 used in the current study was based on a previous study in which infusion of GLP-1 at 1.2 pmol/kg/min achieved fasting normoglycaemia, and was well tolerated in postoperative patients with type 2 diabetes [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="20175" xml_f="20177" txt_i="12450" txt_f="12452">11</offsets></xref><offsets xml_i="20184" xml_f="20349" txt_i="12452" txt_f="12617">]. Hyperglycaemia in critically ill patients, not previously known to have diabetes, is associated with poorer outcomes than in patients with pre-existing diabetes [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="20381" xml_f="20383" txt_i="12617" txt_f="12619">12</offsets></xref><offsets xml_i="20390" xml_f="20629" txt_i="12619" txt_f="12858">]. Hence, we chose to study the effect of exogenous GLP-1 in these patients. Insulin infusions were ceased two hours before the commencement of the study to ensure clearance of exogenous insulin. Given the short plasma half life of GLP-1 [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="20661" xml_f="20663" txt_i="12858" txt_f="12860">13</offsets></xref><offsets xml_i="20670" xml_f="20908" txt_i="12860" txt_f="13098">] carry over effects were not anticipated or observed, and a crossover protocol was an appropriate study design. The nutrient type and load were selected on a feeding regimen which aims to deliver 25 kcal/kg/day of mixed nutrient liquid [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="20940" xml_f="20942" txt_i="13098" txt_f="13100">14</offsets></xref><offsets xml_i="20949" xml_f="20987" txt_i="13100" txt_f="13138">]. Accordingly, 1.5 kcal/min of Ensure</offsets><sup><offsets xml_i="20992" xml_f="20994" txt_i="13138" txt_f="13140">® </offsets></sup><offsets xml_i="21000" xml_f="21255" txt_i="13140" txt_f="13395">was administered. Hyperglycaemia in critical illness is believed to reflect inadequate insulin secretion, hepatic and peripheral insulin resistance, and an increase in the counter-regulatory hormones cortisol, catecholamines, glucagon and growth hormone [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="21287" xml_f="21289" txt_i="13395" txt_f="13397">15</offsets></xref><offsets xml_i="21296" xml_f="21506" txt_i="13397" txt_f="13607">]. Only plasma insulin and glucagon concentrations were measured, as GLP-1 is not known to alter the secretion of the other counter-regulatory hormones and the study was designed to establish proof of concept [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="21537" xml_f="21538" txt_i="13607" txt_f="13608">9</offsets></xref><offsets xml_i="21545" xml_f="21547" txt_i="13608" txt_f="13610">].</offsets></p><p><offsets xml_i="21554" xml_f="21608" txt_i="13611" txt_f="13665">Exogenous GLP-1 slows gastric emptying substantially [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="21639" xml_f="21640" txt_i="13665" txt_f="13666">8</offsets></xref><offsets xml_i="21647" xml_f="21746" txt_i="13666" txt_f="13765">] and this may be the dominant mechanism by which GLP-1 reduces postprandial glycaemic excursions [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="21778" xml_f="21780" txt_i="13765" txt_f="13767">16</offsets></xref><offsets xml_i="21787" xml_f="21940" txt_i="13767" txt_f="13920">]. Hence, the magnitude of glucose lowering by GLP-1 is likely to be even greater during gastric, rather than small intestinal, nutrient administration [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="21972" xml_f="21974" txt_i="13920" txt_f="13922">17</offsets></xref><offsets xml_i="21981" xml_f="22172" txt_i="13922" txt_f="14113">]. However, delayed gastric emptying occurs in approximately 50% of critically ill patients and, when marked, may lead to under-nutrition, gastro-oesophageal reflux and pulmonary aspiration [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="22204" xml_f="22206" txt_i="14113" txt_f="14115">18</offsets></xref><offsets xml_i="22213" xml_f="22496" txt_i="14115" txt_f="14398">]. Given the above considerations it was appropriate to initially determine whether GLP-1 attenuates the glycaemic response to small intestinal, rather than intra-gastric, nutrient. Whether GLP-1 will slow gastric emptying further in critically ill patients remains to be determined.</offsets></p><p><offsets xml_i="22503" xml_f="22731" txt_i="14399" txt_f="14627">It should be recognised that nutrient-induced hyperglycaemia was only attenuated, and not suppressed completely by GLP-1. This may potentially reflect an insufficient GLP-1 dose, and larger doses are known to be well tolerated [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="22763" xml_f="22765" txt_i="14627" txt_f="14629">19</offsets></xref><offsets xml_i="22772" xml_f="23522" txt_i="14629" txt_f="15379">]. As discussed, given the effect of GLP-1, to slow gastric emptying, it is possible that the magnitude of glucose lowering will be greater during gastric feeding. However, some critically ill patients may also have inadequate β-cell reserve to compensate for the disordered hormone milieu even at larger doses and/or during gastric feeding. Given the complexity and severity of disordered glucose metabolism in the critically ill, and an ongoing requirement for nutrition, it is anticipated that exogenous GLP-1 may achieve normoglycaemia only in specific sub-groups of patients. However, this study establishes the concept that GLP-1 as sole therapy, or in combination with insulin, has the potential to manage hyperglycaemia in the critically ill.</offsets></p><p><offsets xml_i="23529" xml_f="24025" txt_i="15380" txt_f="15876">We elected to evaluate the effects of an acute GLP-1 infusion in a relatively small, heterogeneous cohort of critically ill patients studied at various times after their admission. This limitation should be recognised and may have been of greater relevance if the study outcome had been negative, rather than positive. Although our study only measured the effect of a short-term infusion, it is likely that the glucose-lowering effect would persist for the entire period of GLP-1 administration [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="24057" xml_f="24059" txt_i="15876" txt_f="15878">20</offsets></xref><offsets xml_i="24066" xml_f="25031" txt_i="15878" txt_f="16843">]. Furthermore, we speculate that longer-term GLP-1 infusion may result in less glycaemic variability than the current approach to insulin therapy, because of its effects on both insulin and glucagon. An additional limitation is the inconclusive evidence regarding insulin stimulation and glucagon suppression. Although there were no observed differences in absolute insulin concentrations during the entire GLP-1 infusion, there was an increase in the insulin/glucose ratio and transient suppression of glucagon secretion. Moreover, the number of subjects included was based on power calculations for a glucose-lowering effect and the study may have been underpowered to establish effects on insulin and glucagon over the entire study period. Given the positive outcome of this study, additional studies are required to further elucidate the mechanisms underlying the effects of GLP-1 and determine the optimal dose and duration of treatment in the critically ill.</offsets></p></sec><sec><title><offsets xml_i="25053" xml_f="25064" txt_i="16845" txt_f="16856">Conclusions</offsets></title><p><offsets xml_i="25075" xml_f="25441" txt_i="16857" txt_f="17223">This study establishes that exogenous GLP-1 infusion limits the peak blood glucose, and markedly attenuates the overall glycaemic response, during small intestinal feeding, in non-diabetic critically ill patients. Given exogenous GLP-1 may improve the safety and efficacy of glycaemic control in this group, further investigation into its potential use is warranted.</offsets></p></sec><sec><title><offsets xml_i="25463" xml_f="25475" txt_i="17225" txt_f="17237">Key messages</offsets></title><p><offsets xml_i="25486" xml_f="25601" txt_i="17238" txt_f="17353">• The effects of exogenous GLP-1 are glucose dependent, thus the use of GLP-1 is not associated with hypoglycaemia.</offsets></p><p><offsets xml_i="25608" xml_f="25725" txt_i="17354" txt_f="17471">• Exogenous GLP-1 markedly attenuates the glycaemic response to small intestinal nutrient in critically ill patients.</offsets></p><p><offsets xml_i="25732" xml_f="25877" txt_i="17472" txt_f="17617">• Exogenous GLP-1 is a novel therapy to treat hyperglycaemia and further investigation into its potential use in the critically ill is warranted.</offsets></p></sec><sec><title><offsets xml_i="25899" xml_f="25912" txt_i="17619" txt_f="17632">Abbreviations</offsets></title><p><offsets xml_i="25923" xml_f="26074" txt_i="17633" txt_f="17784">AUC: area under the curve; CV: coefficient of variation; ELISA: enzyme linked immunosorbent assay; GLP-1: glucagon-like peptide-1; NS: not significant.</offsets></p></sec><sec><title><offsets xml_i="26096" xml_f="26115" txt_i="17786" txt_f="17805">Competing interests</offsets></title><p><offsets xml_i="26126" xml_f="26184" txt_i="17806" txt_f="17864">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="26206" xml_f="26228" txt_i="17866" txt_f="17888">Authors' contributions</offsets></title><p><offsets xml_i="26239" xml_f="26686" txt_i="17889" txt_f="18336">AD was the main contributor to study design, acquisition, analysis and interpretation of the data and drafting the manuscript. MJC and RF contributed to study conception and revision of manuscript. CB and LKB were responsible for data acquisition and analysis and contributed to revision of manuscript. MH was the main contributor to study conception and participated in drafting the manuscript. All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="26708" xml_f="26728" txt_i="18338" txt_f="18358">Authors' information</offsets></title><p><offsets xml_i="26739" xml_f="27051" txt_i="18359" txt_f="18671">AD is an intensivist enrolled as a PhD student at the University of Adelaide. His thesis studies the effects of incretin hormones in critically ill patients. He is supervised by MJC, RJF and MH. The results were presented in abstract form at the 2008 meeting of the Australian New Zealand Intensive Care Society.</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>AD is supported by a University of Adelaide/Royal Adelaide Hospital Co-funded Dawes Scholarship. This study was supported by a research grant from the Australian New Zealand Collage of Anaesthetists. The authors are grateful for the assistance provided by Ms Sharon Yap (Department of Pharmacy Royal Adelaide Hospital) for randomisation, preparation and blinding of study drug, Ms Judith Wishart (Discipline of Medicine University of Adelaide) for analysis of insulin and GLP-1 concentrations and Mr Kris Tan (Department of Endocrinology Royal Prince Alfred Hospital Sydney) for analysis of glucagon concentrations.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Umpierrez</surname><given-names>GE</given-names></name><name><surname>Isaacs</surname><given-names>SD</given-names></name><name><surname>Bazargan</surname><given-names>N</given-names></name><name><surname>You</surname><given-names>X</given-names></name><name><surname>Thaler</surname><given-names>LM</given-names></name><name><surname>Kitabchi</surname><given-names>AE</given-names></name></person-group><article-title>Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>978</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">11889147</pub-id><pub-id pub-id-type="doi">10.1210/jc.87.3.978</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berghe</surname><given-names>G van den</given-names></name><name><surname>Wouters</surname><given-names>P</given-names></name><name><surname>Weekers</surname><given-names>F</given-names></name><name><surname>Verwaest</surname><given-names>C</given-names></name><name><surname>Bruyninckx</surname><given-names>F</given-names></name><name><surname>Schetz</surname><given-names>M</given-names></name><name><surname>Vlasselaers</surname><given-names>D</given-names></name><name><surname>Ferdinande</surname><given-names>P</given-names></name><name><surname>Lauwers</surname><given-names>P</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name></person-group><article-title>Intensive insulin therapy in the critically ill patients</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">11794168</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa011300</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brunkhorst</surname><given-names>FM</given-names></name><name><surname>Engel</surname><given-names>C</given-names></name><name><surname>Bloos</surname><given-names>F</given-names></name><name><surname>Meier-Hellmann</surname><given-names>A</given-names></name><name><surname>Ragaller</surname><given-names>M</given-names></name><name><surname>Weiler</surname><given-names>N</given-names></name><name><surname>Moerer</surname><given-names>O</given-names></name><name><surname>Gruendling</surname><given-names>M</given-names></name><name><surname>Oppert</surname><given-names>M</given-names></name><name><surname>Grond</surname><given-names>S</given-names></name><name><surname>Olthoff</surname><given-names>D</given-names></name><name><surname>Jaschinski</surname><given-names>U</given-names></name><name><surname>John</surname><given-names>S</given-names></name><name><surname>Rossaint</surname><given-names>R</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Schaefer</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>P</given-names></name><name><surname>Kuhnt</surname><given-names>E</given-names></name><name><surname>Kiehntopf</surname><given-names>M</given-names></name><name><surname>Hartog</surname><given-names>C</given-names></name><name><surname>Natanson</surname><given-names>C</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><collab>German Competence Network Sepsis (SepNet)</collab></person-group><article-title>Intensive insulin therapy and pentastarch resuscitation in severe sepsis</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>125</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">18184958</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa070716</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name><name><surname>Bigger</surname><given-names>JT</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Genuth</surname><given-names>S</given-names></name><name><surname>Ismail-Beigi</surname><given-names>F</given-names></name><name><surname>Grimm</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name><surname>Probstfield</surname><given-names>JL</given-names></name><name><surname>Simons-Morton</surname><given-names>DG</given-names></name><name><surname>Friedewald</surname><given-names>WT</given-names></name></person-group><article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2545</fpage><lpage>2559</lpage><pub-id pub-id-type="pmid">18539917</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa0802743</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heyland</surname><given-names>DK</given-names></name><name><surname>Dhaliwal</surname><given-names>R</given-names></name><name><surname>Drover</surname><given-names>JW</given-names></name><name><surname>Gramlich</surname><given-names>L</given-names></name><name><surname>Dodek</surname><given-names>P</given-names></name></person-group><article-title>Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2003</year><volume>27</volume><fpage>355</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">12971736</pub-id><pub-id pub-id-type="doi">10.1177/0148607103027005355</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Preiser</surname><given-names>JC</given-names></name><name><surname>Devos</surname><given-names>P</given-names></name></person-group><article-title>Clinical experience with tight glucose control by intensive insulin therapy</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>S503</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">17713400</pub-id><pub-id pub-id-type="doi">10.1097/01.CCM.0000278046.24345.C7</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Heimesaat</surname><given-names>MM</given-names></name><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Ebert</surname><given-names>R</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group><article-title>Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus</article-title><source>J Clin Invest</source><year>1993</year><volume>91</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">8423228</pub-id><pub-id pub-id-type="doi">10.1172/JCI116186</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>TJ</given-names></name><name><surname>Pilichiewicz</surname><given-names>AN</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>KL</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Wishart</surname><given-names>J</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Feinle-Bisset</surname><given-names>C</given-names></name></person-group><article-title>Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>1916</fpage><lpage>1923</lpage><pub-id pub-id-type="pmid">16492694</pub-id><pub-id pub-id-type="doi">10.1210/jc.2005-2220</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Heimesaat</surname><given-names>MM</given-names></name><name><surname>Behle</surname><given-names>K</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Nauck</surname><given-names>MS</given-names></name><name><surname>Ritzel</surname><given-names>R</given-names></name><name><surname>Hufner</surname><given-names>M</given-names></name><name><surname>Schmiegel</surname><given-names>WH</given-names></name></person-group><article-title>Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>1239</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">11889194</pub-id><pub-id pub-id-type="doi">10.1210/jc.87.3.1239</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>JJ</given-names></name><name><surname>Gethmann</surname><given-names>A</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Gotze</surname><given-names>O</given-names></name><name><surname>Schmitz</surname><given-names>F</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Gallwitz</surname><given-names>B</given-names></name><name><surname>Schmidt</surname><given-names>WE</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans</article-title><source>Am J Physiol Endocrinol Metab</source><year>2006</year><volume>290</volume><fpage>E1118</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">16403774</pub-id><pub-id pub-id-type="doi">10.1152/ajpendo.00576.2005</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>JJ</given-names></name><name><surname>Weyhe</surname><given-names>D</given-names></name><name><surname>Michaely</surname><given-names>M</given-names></name><name><surname>Senkal</surname><given-names>M</given-names></name><name><surname>Zumtobel</surname><given-names>V</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Schmidt</surname><given-names>WE</given-names></name><name><surname>Gallwitz</surname><given-names>B</given-names></name></person-group><article-title>Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><fpage>848</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">15090972</pub-id><pub-id pub-id-type="doi">10.1097/01.CCM.0000114811.60629.B5</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egi</surname><given-names>M</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Stachowski</surname><given-names>E</given-names></name><name><surname>French</surname><given-names>CJ</given-names></name><name><surname>Hart</surname><given-names>GK</given-names></name><name><surname>Hegarty</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name></person-group><article-title>Blood glucose concentration and outcome of critical illness: the impact of diabetes</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>2249</fpage><lpage>2255</lpage><pub-id pub-id-type="pmid">18664780</pub-id><pub-id pub-id-type="doi">10.1097/CCM.0b013e318181039a</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilsboll</surname><given-names>T</given-names></name><name><surname>Agerso</surname><given-names>H</given-names></name><name><surname>Krarup</surname><given-names>T</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">12519856</pub-id><pub-id pub-id-type="doi">10.1210/jc.2002-021053</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>RD</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Heyland</surname><given-names>DK</given-names></name></person-group><article-title>Feeding critically ill patients: what is the optimal amount of energy?</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>S535</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">17713405</pub-id><pub-id pub-id-type="doi">10.1097/01.CCM.0000279204.24648.44</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marik</surname><given-names>PE</given-names></name><name><surname>Raghavan</surname><given-names>M</given-names></name></person-group><article-title>Stress-hyperglycemia, insulin and immunomodulation in sepsis</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">14991101</pub-id><pub-id pub-id-type="doi">10.1007/s00134-004-2167-y</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>To be or not to be–an incretin or enterogastrone?</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>148</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">16407380</pub-id><pub-id pub-id-type="doi">10.1136/gut.2005.071787</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>JJ</given-names></name><name><surname>Kemmeries</surname><given-names>G</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>2212</fpage><lpage>2218</lpage><pub-id pub-id-type="pmid">15983224</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.54.7.2212</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>A</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Fraser</surname><given-names>RJ</given-names></name><name><surname>Bryant</surname><given-names>LK</given-names></name><name><surname>Burgstad</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>NQ</given-names></name></person-group><article-title>Mechanisms underlying feed intolerance in the critically ill: Implications for treatment</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><fpage>3909</fpage><lpage>3917</lpage><pub-id pub-id-type="pmid">17663503</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mussig</surname><given-names>K</given-names></name><name><surname>Oncu</surname><given-names>A</given-names></name><name><surname>Lindauer</surname><given-names>P</given-names></name><name><surname>Heininger</surname><given-names>A</given-names></name><name><surname>Aebert</surname><given-names>H</given-names></name><name><surname>Unertl</surname><given-names>K</given-names></name><name><surname>Ziemer</surname><given-names>G</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><name><surname>Gallwitz</surname><given-names>B</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes</article-title><source>Am J Cardiol</source><year>2008</year><volume>102</volume><fpage>646</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">18721530</pub-id><pub-id pub-id-type="doi">10.1016/j.amjcard.2008.06.029</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zander</surname><given-names>M</given-names></name><name><surname>Madsbad</surname><given-names>S</given-names></name><name><surname>Madsen</surname><given-names>JL</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>824</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">11897280</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(02)07952-7</pub-id></citation></ref></ref-list></back></article>